Mehmet COŞKUN

İNTRAVİTREAL ENJEKSİYON HASTALARINDA BLEFAROSTA TİPİNİN GÖZİÇİ BASINCINA ETKİSİ The Effect of Eye Speculum Type on the Intraocular Pressure in Intravitreal Injection Patients

ÖZET

Anahtar Kelimeler:

İNTRAVİTREAL ENJEKSİYON HASTALARINDA BLEFAROSTA TİPİNİN GÖZİÇİ BASINCINA ETKİSİ The Effect of Eye Speculum Type on the Intraocular Pressure in Intravitreal Injection Patients

PDF

___

1. Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye (Lond) 2012;26:1-16. 2. Alakuş MF, Taş M, Öner V, İşcan Y, Türkçü FM, Şimşek A, et al. Diabetik Maküla Ödeminde İntravitreal Bevacizumab Etkinliğininin Değerlendirilmesi. Retina Vitreus 2012;1:35-40 3. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 2009;23:181-185. 4. Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 2010;20:174- 179. 5. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl . Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007;85:777-781. 6. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18:658- 661. 7. Höhn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol 2010;248:1371-1375. 8. Shingleton BJ, Pasternack JJ, Hung JW, O’Donoghue MW. Three- and five year changes in intraocular pressures after clear corneal phacoemulsification in open angle glaucoma patients, glaucoma suspects, and normal patients. J Glaucoma 2006;15:494-498. 9. Poley BJ, Lindstrom RL, Samuelson TW. Long term effects of phacoemulsification with intraocular lens implantation in normotensive and ocular hypertensive eyes. J Cataract Refract Surg 2008;34:735-742. 10. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) 2011;25:661-72